BioSpace News Archive

Palisade Bio, Inc. announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 12:00 PM ET.

Adolore BioTherapeutics, a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 10:00 AM ET.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel

Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company developing N-myristoyltransferase (NMT) inhibitors to treat hematologic cancers and solid tumors.

The U.S. Department of Justice and the U.S. Food and Drug Administration announced the creation of a federal multi-agency task force to combat the illegal distribution and sale of e-cigarettes.

Arcutis Biotherapeutics, Inc. announced new results from the INTEGUMENT-OLE long-term open-label study of investigational once-daily roflumilast cream 0.15% in adults and children ages 6 years and older with AD presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference.

In the presence of the esteemed Christopher Skeete, Minister for the Economy, and Christine Poirier, Laval City Councillor, , Corealis Pharma Inc. proudly inaugurates the expansion of its facilities nestled in the heart of Laval’s Biotech City.

ProKidney Corp. announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses.

Vicarious Surgical Inc. announced it will effect a 1-for-30 reverse stock split of the Company’s issued and outstanding Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share.

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.